High Risk Populations Among COPD Patients in Japan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1016 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The patients with complications of COPD and asthma have features mixed with two diseases, COPD and asthma. Therefore, the outcomes are worsened if the patients with COPD have symptoms overlapped with asthma, however, no sufficient data exist in Japan for estimating the prevalence of ACOS in patients with COPD. The primary objective of this NIS is to clarify the proportion of ACOS defined by GINA and GOLD in patients with COPD. The main secondary objectives are To explore the features of history of COPD exacerbations, symptoms, eosinophilic inflammation and patient background in patients with ACOS, to clarify the history of COPD exacerbations in patients with COPD, to evaluate the degrees of eosinophilic inflammation of the respiratory tract in patients with COPD and to evaluate the symptoms in patients with COPD. This is a cross-sectional study targeting COPD patients receiving outpatient treatment and follow-up by physicians in Japan. FSI is scheduled as 2Q 2015 and DBL would be locked by 3Q 2015.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society

NCT03577795

Pulmonary Disease, Chronic Obstructive

COMPLETED

The Mixed Phenotype of Asthma and COPD: the Overlap Syndrome

NCT03817333

Asthma COPD

COMPLETED

Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)

NCT02302417

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan

NCT03957577

Pulmonary Disease, Chronic Obstructive

COMPLETED

Identifying Patients With the COPD-Asthma Overlap Phenotype: Therapeutic Implications

NCT02985814

COPD Asthma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Site(s), number of subjects planned Number of study sites planned for this research study (scheduled) 60 (undetermined) Number of subjects planned for this research study (scheduled) 1,100 patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a diagnosis of COPD (FEV1/FVC\<0.7 confirmed based on the past medical records)
* Patients aged 40 years and over at the diagnosis of COPD
* Outpatient
* 10 or more pack-years of current or former smokers
* Patients who have traceable medical records of COPD (including the results of spirometry) going back more than a year
* Patients who meet any of the following two criteria

1. Patients who have medical records of the results of spirometry at more than two different time points excluding the time point of COPD exacerbations\* for the past 3 years
2. Patients who can provide the results of reversibility testing for respiratory tract
* Patients who give written informed consent regarding the participation in this study

Exclusion Criteria

* Patients currently with COPD exacerbations
* Patients who currently enroll in the other interventional study including clinical trials
* Patients who concurrently develop or have a history of lung cancer
* Patients who are disabled to understand the study procedure or answer the questionnaire (i.e. due to the history of alcohol or drug abuse)

Minimum Eligible Age

40 Years

Maximum Eligible Age

150 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No